Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
International Journal of Molecular Sciences · 25.04.2023 · 24 (9) · 7849
DOI: 10.3390/ijms24097849 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.04.2023. Verfasst von Francesco Amati und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital capacity and the risk of acute exacerbation among patients with idiopathic pulmonary fibrosis. Recent data suggest that different interstitial lung diseases with a progressive pulmonary fibrosis phenotype can share similar pathogenetic and biological pathways and could be amenable to antifibrotic therapies. Indeed, historical management strategies in interstitial lung disease have failed to identify potential treatments once progression has occurred despite available drugs. In this systematic review, we summarized data on the efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis as well as ongoing and upcoming clinical trials. We identify two well-designed trials regarding nintedanib demonstrating the efficacy of this drug in slowing disease progression in patients with interstitial lung diseases other than idiopathic pulmonary fibrosis. On the other hand, results on the use of pirfenidone in interstitial lung diseases other than idiopathic pulmonary fibrosis should be interpreted with more caution on the basis of trial limitations. Several randomized control trials are underway to improve the quality of evidence in the interstitial lung disease field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
- Respiratory Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
- Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy.
ORCID-Profile: Francesco Amati, Anna Stainer, Andrea Gramegna, Francesco Blasi
Zitieren
APA
Amati, F., Stainer, A., Polelli, V., Mantero, M., Gramegna, A., Blasi, F., & Aliberti, S. (2023). Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. International Journal of Molecular Sciences, 24(9), 7849. https://doi.org/10.3390/ijms24097849
Vancouver
Amati F, Stainer A, Polelli V, Mantero M, Gramegna A, Blasi F, et al. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. International Journal of Molecular Sciences. 2023;24(9):7849. doi:10.3390/ijms24097849
BibTeX
@article{Amati2023,
author = {Amati, Francesco and Stainer, Anna and Polelli, Veronica and Mantero, Marco and Gramegna, Andrea and Blasi, Francesco and Aliberti, Stefano},
title = {Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {9},
pages = {7849},
doi = {10.3390/ijms24097849}
}
EUVIMED